The stock of Entero Therapeutics Inc (ENTO) has seen a -6.79% decrease in the past week, with a 10.75% gain in the past month, and a -18.75% decrease in the past quarter. The volatility ratio for the week is 15.29%, and the volatility levels for the past 30 days are at 10.80% for ENTO. The simple moving average for the last 20 days is 3.14% for ENTO stock, with a simple moving average of -17.54% for the last 200 days.
Is It Worth Investing in Entero Therapeutics Inc (NASDAQ: ENTO) Right Now?
The 36-month beta value for ENTO is also noteworthy at 0.79. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENTO is 4.67M, and at present, short sellers hold a 6.73% of that float. The average trading volume of ENTO on May 22, 2025 was 678.80K shares.
ENTO) stock’s latest price update
The stock price of Entero Therapeutics Inc (NASDAQ: ENTO) has surged by 1.47 when compared to previous closing price of 0.40, but the company has seen a -6.79% decline in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-03-24 that Boca Raton, Florida–(Newsfile Corp. – March 24, 2025) – Entero Therapeutics, Inc. (NASDAQ: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the “Rescission Agreement”) with 100% of the previous shareholders of ImmunogenX, LLC (“IMGX”) in relation to the ImmunogenX Business Combination which was previously announced on December 18, 2023 and ultimately closed on March 14, 2024. The Rescission Agreement and its effects are subject to certain closing conditions, including Entero receiving shareholder approval which must occur on or before June 30, 2025.
ENTO Trading at -7.24% from the 50-Day Moving Average
After a stumble in the market that brought ENTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.60% of loss for the given period.
Volatility was left at 10.80%, however, over the last 30 days, the volatility rate increased by 15.29%, as shares surge +8.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.80% lower at present.
During the last 5 trading sessions, ENTO fell by -4.65%, which changed the moving average for the period of 200-days by -36.91% in comparison to the 20-day moving average, which settled at $0.3891. In addition, Entero Therapeutics Inc saw -35.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTO starting from Romano Sarah, who sale 727 shares at the price of $0.64 back on Jan 06 ’25. After this action, Romano Sarah now owns 17,287 shares of Entero Therapeutics Inc, valued at $465 using the latest closing price.
Romano Sarah, the Chief Financial Officer of Entero Therapeutics Inc, sale 476 shares at $0.45 during a trade that took place back on Oct 09 ’24, which means that Romano Sarah is holding 18,014 shares at $212 based on the most recent closing price.
Stock Fundamentals for ENTO
The total capital return value is set at -0.27. Equity return is now at value -33.24, with -25.32 for asset returns.
Based on Entero Therapeutics Inc (ENTO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -65.59. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -237.88.
Currently, EBITDA for the company is 15606.71 with net debt to EBITDA at 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
In summary, Entero Therapeutics Inc (ENTO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
